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probability of receiving rasburicase and is calculated from a non-parse logistic regres-
sion model that is adjusted for age, demographics, lab tests, ICU admission, Charlson 
Comorbidity Index, hospital characteristics, and other factors. Each rasburicase 
patient’s PS is matched via a 5:1 digit Greedy algorithm to that of an allopurinol 
patient to reduce confounding. Alternatively, the PS is added as another predictor in 
a non-parse Generalized Linear Model when estimating the effect of rasburicase on 
outcomes. RESULTS: Of 8,257 patients, 71 rasburicase patients met our inclusion 
criteria and were matched to 71 allopurinol patients. Before matching, the median 
[25th, 75th percentile] total costs of rasburicase patients vs. allopurinol patients were 
$30,681 [$17,259, $58,241] vs. $18,106 [$8,937, $39,084]. After initial matching, 
median costs were lower with rasburicase: only $30,681, vs. $58,438 (P = 0.007), 
while pre-Rx minus post-Rx mean UA differences were signiﬁcantly greater with 
rasburicase vs allopurinol (9.3 vs. 0.9 mg/dL, P < 0.001). CONCLUSIONS: Multivari-
ate PS adjustment reduces selection bias and confounding when quantifying treatment 
effects of drug therapies. A preliminary PS analysis demonstrated that rasburicase 
was associated with greater UA reduction than allopurinol, as well as lower medical 
care costs.
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OBJECTIVES: Examine the effectiveness of using prophylactic G-CSF among NHL 
patients treated with anthracycline-based chemotherapy in practice. METHODS: 
Using the national Surveillance, Epidemiology and End Results (SEER)-Medicare 
linked database, we studied patients 66 years or older diagnosed as NHL and on 
anthracycline in one of the 13 SEER registry areas from 1994–2002. Prophylactic 
G-CSF use was designated if a patient had a G-CSF claim within the ﬁrst 5 days of 
the ﬁrst chemotherapy cycle. Neutropenia hospitalization (NH) was identiﬁed within 
6 months of diagnosis. Multiple regression estimates were used to examine whether 
treated patients actually beneﬁted. Instrumental variable estimates using local area 
prophylactic G-CSF treatment rates as instruments were used to estimate whether 
increases in the G-CSF utilization rate could lead to further reductions in the rate of 
neutropenic hospitalization. RESULTS: Only 9.83% of study patients had early 
G-CSF. After adjustment for patient demographic and clinical risk factors, multiple 
regressions indicated prophylactic G-CSF signiﬁcantly reduced NH events for the 
patients who received G-CSF (OR = 0.54, 95% CI = 0.34–0.87). Chow F-statistics 
showed our instrumental variable described a statistically signiﬁcant portion in the 
variation in G-CSF use (F = 14.65, P = 0.0001). Our instrumental variable estimates 
were not statistically signiﬁcant from zero. CONCLUSIONS: Among elderly NHL 
patients on anthracycline-based chemotherapy, our multiple regression estimates 
suggest that prophylactic G-CSF treated patients reduced their neutropenia risk. 
However, our instrumental variable results suggest that expanding prophylactic 
G-CSF use rates will not signiﬁcantly reduce NH rates. These results suggest that 
providers optimally sorted the use of G-CSF patients to those patients that are most 
apt to gain.
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BACKGROUND: Retrospective observational studies are often the only practical way 
to assess drug effects on uncommon diagnoses. However, because treatment assign-
ment is not randomized, selection bias and confounding can distort the effect esti-
mates. A new multivariate statistical method based on the Propensity Score (PS) of 
receiving treatment minimizes this bias. METHODS: This case-control study used the 
Health Facts® database (Cerner Corporation; Kansas City, MO), which integrates 
patient information from hospitals throughout the United States. Cancer patients 
receiving rasburicase or a combination of rasburicase and allopurinol were eligible for 
study inclusion. Both therapies reduce uric acid (UA) elevation otherwise resulting 
from tumor lysis syndrome. The PS is the probability of receiving rasburicase and is 
calculated from a non-parse logistic regression model that adjusts for age, demograph-
ics, lab tests, ICU admission, Charlson Comorbidity Index, hospital characteristics, 
and other factors. Each rasburicase patient’s PS was matched via a 5:1 digit Greedy 
algorithm to that of a Combination patient. Alternatively, the PS was added as another 
predictor in a non-parse Generalized Linear Model when estimating the effect of 
rasburicase on outcomes. RESULTS: Of 71 rasburicase and 123 combination patients, 
47 matched pairs were created. Differences in confounders by group were non-signif-
icant after matching. Before matching, the median [25th, 75th percentile] total costs of 
rasburicase patients vs. combination patients were $30,681 [$17,259, $58,241] vs. 
$54,862 [$25,907, $108,454]. After initial matching, rasburicase patients had lower 
median costs ($32,831 vs. $73,226; P = 0.02) and greater pre-Rx (baseline) minus 
post-Rx mean differences in UA levels (9.0 vs. 2.5 mg/dL; P = 0.004). CONCLU-
SIONS: Multivariate PS adjustment reduces confounding when quantifying treatment 
effects of drug therapies. A preliminary PS analysis demonstrated that rasburicase 
monotherapy was associated with greater UA reduction than rasburicase-allopurinol 
combination, when either is administered in the context of TLS management in a 
“real-world” clinical setting.
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OBJECTIVES: The Center for Comparative Effectiveness Research in Cancer Genom-
ics (CANCERGEN) is a multi-disciplinary, national consortium established with the 
aim of generating high-quality evidence on the clinical utility and economic value of 
Genomics and Personalized Medicine (GPM) applications. This type of effort requires 
horizon scaning to identify promising candidates for evaluation in a randomized 
controlled trial (RCT). METHODS: A search of the peer-reviewed literature was 
performed using MEDLINE. Keywords included terms likely to be included in studies 
reporting the results of genomic-based prognostication and prediction for cancer. 
References were restricted to the last ﬁve years to identify technologies sufﬁciently 
developed to be appropriate for study in a RCT. The search was restricted to the ﬁve 
cancers with the highest prevalence and to key clinical journals (Abridged Index 
Medicus), as the unrestricted literature would identify targets too early in the develop-
ment cycle for a RCT. The peer-reviewed literature was supplemented by searching 
the “grey” literature including major conferences in cancer for the last two years, 
allowing for inclusion of technologies which have not entered the peer-reviewed litera-
ture. The results were further analyzed for relevance using criteria such as: the title/
abstract containing reference to a new/existing genetic test, biomarkers or gene targets 
relevant to cancer prognostication and/or effectiveness of existing/potential adjuvant 
therapy. RESULTS: In the peer-reviewed literature, our search strategy indicated 199 
references matching our keyword search and restrictions. After application of criteria 
above, the list was reduced to 71 candidates. As an example of the “grey” literature 
search, 42 additional results were obtained from a search of the San Antonio Breast 
Cancer Conference (2008). CONCLUSIONS: A horizon scanning study is needed to 
identify genetic-based technologies for cancer, for which CER can be performed in a 
RCT. The results from this horizon-scan will drive development of new GPM trial 
designs incorporating CER.
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OBJECTIVES: A randomized trial comparing doxetaxel (D) and paclitaxel (P) treated 
patients has shown greater neurologic toxicity with P given weekly. This study aimed 
to compare neuropathy (NP) and NP-related outcomes between D and P in a com-
munity practice. METHODS: The analysis was conducted using the Georgia Cancer 
Specialist Database (2003–2008) supplemented by chart abstraction. Patients with 
stage I-III breast cancer (BC) and treated with adjuvant D or P-containing chemo-
therapy (CT) were followed from initial treatment to the earliest of death, loss to 
follow-up, or switch to other regimens. NP and NP-related outcomes were measured 
as (1) 6-month rate of severe NP (CTC grade 3/4), (2) 6-month rate of receiving NP-
related medications (NPMs), (3) proportion of patients whose CT was affected due 
to NP (CT being held, discontinued, or dose reduction). Univariate and multivariate 
analyses with adjustment of clinical and demographic characteristics were performed 
to compare the outcomes between D and P groups. RESULTS: A total of 591 (63.6%) 
and 338 patients treated with D and P were included. The univariate analyses showed 
that P had higher rates of severe NP (4.9% vs. 1.0%) and NPMs use (28.1% vs. 7.6%) 
within 6 months, and their CT was more likely to be affected (7.1% vs. 1.5%), 
compared with D group (all p < 0.001). Similarly, the adjusted results (all p < 0.001) 
showed that P was at higher risks for severe NP (HR = 3.50), NPMs use (HR = 6.40), 
and CT interruption (OR = 5.40). CONCLUSIONS: This study found that P was 
associated with higher risks for severe NP and CT interruption, compared to D. The 
ﬁndings are consistent with published trials and call for close observation of NP when 
using P. The results should also be viewed in the context that NP poses higher eco-
nomic burden over non-NP patients. The ﬁndings need to be conﬁrmed by addition 
studies from community settings.
